Nastoupil, L. J. Et Al. 2023. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Advances , vol.7, no.22 , 7141-7150.

Nastoupil, L. J., Hess, G., Pavlovsky, M. A., Danielewicz, I., Freeman, J., García-Sancho, A. M., ... Glazunova, V.(2023). Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Advances , vol.7, no.22, 7141-7150.

Nastoupil, Loretta Et Al. "Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma," Blood Advances , vol.7, no.22, 7141-7150, 2023

Nastoupil, Loretta J. Et Al. "Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma." Blood Advances , vol.7, no.22, pp.7141-7150, 2023

Nastoupil, L. J. Et Al. (2023) . "Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma." Blood Advances , vol.7, no.22, pp.7141-7150.

@article{article, author={Loretta J. Nastoupil Et Al. }, title={Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma}, journal={Blood Advances}, year=2023, pages={7141-7150} }